{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:02:43Z","timestamp":1787508163427,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejphar.2025.178243","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T22:09:37Z","timestamp":1760393377000},"page":"178243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Adapalene as an anticancer agent: A systematic review and meta-analysis of in vitro and in vivo studies"],"prefix":"10.1016","volume":"1007","author":[{"given":"Ammar","family":"Khalid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-2544","authenticated-orcid":false,"given":"Homa","family":"Fatma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178243_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4155\/ppa-2021-0021","article-title":"Drug repurposing of adapalene for melanoma treatment","volume":"11","author":"Anaya-Ruiz","year":"2022","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.ejphar.2025.178243_bib2","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.3390\/cancers15164136","article-title":"In silico, in vitro, and in vivo investigations on adapalene as repurposed third generation retinoid against multiple myeloma and leukemia","volume":"15","author":"Boulos","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178243_bib3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2025.178243_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1415224","article-title":"Multidimensional role of adapalene in regulating cell death in multiple myeloma","volume":"15","author":"Cao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178243_bib5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ccell.2024.02.004","article-title":"Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells","volume":"42","author":"Colucci","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2025.178243_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2023.108007","article-title":"Targeting AR-positive breast cancer cells via drug repurposing approach","volume":"108","author":"Dutta","year":"2024","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.178243_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10555-023-10144-9","article-title":"Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?","volume":"43","author":"Fatma","year":"2024","journal-title":"Cancer Metast. Rev"},{"key":"10.1016\/j.ejphar.2025.178243_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ejphar.2025.178243_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114239","article-title":"Drug repositioning: progress and challenges in drug discovery for various diseases","volume":"234","author":"Hua","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178243_bib10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3390\/biomedicines12051059","article-title":"Structure\u2013activity relationships and therapeutic applications of retinoids in view of potential benefits from drug repurposing process","volume":"12","author":"Kawczak","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.178243_bib11","article-title":"Novel use of adapalene in treating esophageal cancer and gastrointestinal stromal tumor","author":"Lin","year":"2016","journal-title":"US Patent US20160113895A1"},{"key":"10.1016\/j.ejphar.2025.178243_bib12","series-title":"Methods for the Treatment of Bladder Cancer","author":"Malhotra","year":"2021"},{"key":"10.1016\/j.ejphar.2025.178243_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.958443","article-title":"Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941","volume":"13","author":"Mehraj","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178243_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.801624","article-title":"Adapalene inhibits prostate cancer cell proliferation in vitro and in vivo by inducing DNA damage, S-phase cell cycle arrest, and apoptosis","volume":"13","author":"Nong","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178243_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2003.12.026","article-title":"Potentiated anticancer effects on hepatoma cells by the retinoid adapalene","volume":"208","author":"Ocker","year":"2004","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2025.178243_bib16","series-title":"Apoptosis Inducing Adamantyl Derivatives and their Usage as Anti-cancer Agents","author":"Pfahl","year":"2017"},{"key":"10.1016\/j.ejphar.2025.178243_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2021.746430","article-title":"Development of the SciRAP approach for evaluating the reliability and relevance of in vitro toxicity data","volume":"3","author":"Roth","year":"2021","journal-title":"Front. Toxicol."},{"key":"10.1016\/j.ejphar.2025.178243_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/ph13090217","article-title":"Recent advances regarding the therapeutic potential of adapalene","volume":"13","author":"Rusu","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejphar.2025.178243_bib19","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178243_bib20","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.3892\/mmr.2015.4310","article-title":"Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma","volume":"12","author":"Shi","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2025.178243_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2024.101694","article-title":"Topical retinoid drug adapalene: a new frontier in cancer treatment","volume":"10","author":"Sofi","year":"2024","journal-title":"Results Chem."},{"key":"10.1016\/j.ejphar.2025.178243_bib22","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.3390\/cells9122660","article-title":"Retinoic acid and its derivatives in skin","volume":"9","author":"Szyma\u0144ski","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178243_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103315","article-title":"Adapalene inhibits ovarian cancer ES-2 cells growth by targeting glutamic-oxaloacetic transaminase 1","volume":"93","author":"Wang","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejphar.2025.178243_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:35:11Z","timestamp":1779323711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925009975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":24,"alternative-id":["S0014299925009975"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178243","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adapalene as an anticancer agent: A systematic review and meta-analysis of in vitro and in vivo studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178243"}}